A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin (DQ), which remove old (senescent) cells from the body, suggests that intermittent treatment may hold promise for improving cognitive function in older adults at risk of Alzheimer’s disease.
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM. – Biotech Investments
Spexis AG / Key word(s): Annual Results 31-May-2024 / 22:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is
June 1, 2024